Prokaryotic Expression,Purification and Preparation of Polyclonal Antibody of Human Nek2 Protein

CHEN Qiu-li,YANG Li-chao,LI Hui,WEN Sha,LI Gang,HE Min

China Biotechnology ›› 2020, Vol. 40 ›› Issue (3) : 31-37.

PDF(877 KB)
PDF(877 KB)
China Biotechnology ›› 2020, Vol. 40 ›› Issue (3) : 31-37. DOI: 10.13523/j.cb.1908061
Orginal Article

Prokaryotic Expression,Purification and Preparation of Polyclonal Antibody of Human Nek2 Protein

Author information +
History +

Abstract

Objectives: To express human Nek2 protein by prokaryotic expression system, optimize expression conditions and purify Nek2 protein and prepare anti-Nek2 polyclonal antibody.Methods: The fragment of Nek2 gene was constructed on the prokaryotic expression vector pET30a(+) and transformed into E. coli BL21 (DE3).Expression of the recombinant protein was induced with IPTG and the conditions such as induction temperature, IPTG inducer concentration and induction time were optimized.The protein was purified by staining with 250mmol/L KCl after 12% SDS-PAGE, and the purified Nek2 protein was identified by mass spectrometry.Polyclonal antibody was prepared by immunizing BALB/c mice with purified Nek2 protein, and the titer and specificity of polyclonal antibody was detected by ELISA, Western blot and immunofluorescence assays.Results: The recombinant prokaryotic expression plasmid pET30a(+)-Nek2 was constructed and the recombinant human Nek2 protein was mainly expressed in the form of inclusion bodies.Optimal induction conditions were 28℃,180r/min,IPTG concentration 0.2mmol/L and 32h induction for expression of recombinant protein.The purified protein by mass spectrometry was Nek2 protein, and the concentration of the purified Nek2 protein was 1.35mg/ml.The purified Nek2 protein was used to immunize mice. The titer of polyclonal antibody was greater than 1:243 000 and the polyclonal antibody exhibited a perfect antigenic specificity.Immunofluorescence assay showed that Nek2 was mainly localized in the cytoplasm and nucleus.Conclusion: The recombinant Nek2 protein was used to obtain a anti-Nek2 polyclonal antibody with perfect antigenic specificity.

Key words

Nek2 / Prokaryotic expression / Polyclonal antibody / KCl stain

Cite this article

Download Citations
Qiu-li CHEN, Li-chao YANG, Hui LI, et al. Prokaryotic Expression,Purification and Preparation of Polyclonal Antibody of Human Nek2 Protein[J]. China Biotechnology, 2020, 40(3): 31-37 https://doi.org/10.13523/j.cb.1908061
Nek2[never in mitosis gene-A (NIMA)-related expressed kinase 2]是NIMA相关丝氨酸/苏氨酸蛋白激酶,通过中心体分离调控细胞有丝分裂[1].Nek2异常表达可导致有丝分裂异常,引起染色体不稳定和染色体含量异常[2].目前已有研究发现Nek2在睾丸精原细胞瘤[2],胃癌[3],恶性胶质瘤[4],肺癌[5]等肿瘤组织中过量表达,推测Nek2有可能作为相关肿瘤预后的生物标志物.基于Nek2在肿瘤的发生中发挥着重要作用,因此研发Nek2相关的检测试剂盒具有重要的应用价值.本研究通过原核表达系统成功表达并纯化了Nek2蛋白并制备了抗Nek2多克隆抗体,为进一步研发相关检测试剂盒提供依据.

1 材料与方法

1.1 材 料

pET30a(+)表达质粒,HL7702细胞,huh7细胞和Hep3B细胞由本实验室保存,大肠杆菌BL21 (DE3)和trans5ɑ感受态细胞购自北京全式金生物技术有限公司,PCR引物由北京睿博兴科生物技术有限公司合成,质粒DNA提取试剂盒和DNA纯化试剂盒购自Omega公司,RNA提取试剂盒购自TaKaRa公司,BCA试剂盒和荧光标记的山羊抗小鼠IgG购自碧云天公司,辣根过氧化物酶 (horseradish peroxidase,HRP)标记的山羊抗小鼠IgG购自Thermo公司,BALB/c小鼠购自上海斯莱克实验动物有限责任公司.

1.2 Nek2基因的扩增

按照TaKaRa公司RNA提取试剂盒说明书提取人HL7702细胞 Total RNA.将提取的Total RNA逆转成cDNA.根据Nek2的核酸序列基因合成1~180aa 序列长度,引物由北京睿博兴科生物技术有限公司合成.上游引物:5'-AAAGGATCCATGCCTTCCCGGGCTGAGGACTAT-3'(划线部分为Bam HⅠ酶切位点) ;下游引物:5'-GGGGTCGACAGGTGTGCCAACAAATGTTT-3'(划线部分为SalⅠ酶切位点).取上述引物各0.4μl,高保真pfu DNA 聚合酶 10μl,Nek2 cDNA基因模板2μl,ddH2O 7.2μl,充分混匀后,进行 PCR 反应,反应条件为:95℃ 1min,95℃ 20s,60℃ 20s,72℃ 30s,38 个循环,72℃延伸5min.

1.3 构建pET30a(+)-Nek2载体

将纯化好后的目的基因Nek2和表达质粒pET30a(+)分别进行限制性内切酶 Bam HⅠ和SalⅠ双酶切,酶切产物纯化后用T4连接酶连接,转化大肠杆菌trans5ɑ感受态细胞;将转化菌涂布于卡那霉素(Kan)抗性的琼脂板上,挑取单克隆菌进行Bam HⅠ和SalⅠ双酶切和PCR验证,将阳性克隆菌送广州艾基生物公司进行测序.

1.4 重组人Nek2蛋白在大肠杆菌BL21(DE3)中的表达形式分析

分别将测序正确的阳性重组质粒pET30a(+)-Nek2和表达质粒pET30a(+)转化到大肠杆菌BL21(DE3)中,挑取饱满的单克隆菌转接到Kan抗性的LB培养基中培养过夜,然后按1∶9的比例进行转接,37℃,200r/min培养3h,加入终浓度为1.0mmol/L的异丙基硫代半乳糖苷 (isopropyl β-D-thiogalactoside,IPTG)进行诱导;不加IPTG作为对照.冰上超声破碎离心收集上清,沉淀用PBS重悬.将上清组分和沉淀组分进行12%十二烷基硫酸钠-聚丙烯酰胺凝胶电泳(SDS-PAGE),考马斯亮蓝染色分析,确定重组人Nek2蛋白的表达形式.

1.5 重组人Nek2蛋白表达条件的优化

1.5.1 诱导温度的优化 在阳性重组质粒pET30a(+)-Nek2和表达质粒pET30a(+)的转化菌液中加入终浓度为1.0mmol/L的IPTG进行诱导,分别于18℃ 160r/min,28℃ 180r/min,37℃ 200r/min,42℃ 220r/min不同条件下诱导12h,不加IPTG作为对照.
1.5.2 IPTG终浓度的优化 在阳性重组质粒pET30a(+)-Nek2和表达质粒pET30a(+)的转化菌液中分别加入终浓度为0.2mmol/L,0.4mmol/L,0.6mmol/L,0.8mmol/L,1.0mmol/L的IPTG进行诱导,不加IPTG作为对照.
1.5.3 诱导时间的优化 根据最佳诱导温度和最佳IPTG终浓度,在阳性重组质粒pET30a(+)-Nek2和表达质粒pET30a(+)的转化菌液中加入终浓度为0.2mmol/L的IPTG,诱导时间分别设定为 4h,8h,12h,16h,20h,24h,28h,32h,36h,不加IPTG作为对照.

1.6 重组人Nek2蛋白的纯化和鉴定

根据上述优化条件,将表达好的重组人Nek2蛋白进行12% SDS-PAGE,用250mmol/L KCl染色切胶置PBS缓冲液,4℃摇床过夜.次日吸上层液体即为纯化的人Nek2蛋白溶液,进行12% SDS-PAGE,考马斯亮蓝染色分析,BCA试剂盒蛋白质定量,凝胶成像系统分析纯度,AB Sciex 4800 plus质谱分析纯化后的人Nek2蛋白.

1.7 小鼠免疫

采用皮下多点注射的方法,免疫鼠龄为5周的SPF级雌性BALB/c小鼠.首免 Nek2蛋白剂量为150μg/只,用等体积弗氏完全佐剂混匀后进行免疫,间隔两周免疫一次,第二,三,四次免疫剂量为80μg/只,用等体积弗氏不完全佐剂混匀后进行免疫,第四次免疫后间隔一周,取小鼠尾静脉血,用间接酶联免疫吸附测定实验(ELISA)测定血清效价.

1.8 抗Nek2多克隆抗体效价检测

将1.5μg/ml Nek2蛋白以100μl/孔包被至96孔板,1% BSA封闭,小鼠抗血清以3倍稀释比进行稀释(1∶1 000~1∶243 000),同时设立阴性对照,经HRP-山羊抗小鼠IgG(1∶10 000)孵育,TMB显色,H2SO4终止反应后,测定A450nm吸光度值,以阳性血清(P)/阴性血清(N)A450nm吸光度比值大于2.1的血清最高稀释倍数为免疫小鼠血清效价[6].

1.9 抗Nek2多克隆抗体特异性检测

分别以纯化的Nek2蛋白3μg,2μg,1μg进行10% SDS-PAGE,一抗以抗Nek2多克隆抗体(1∶10 000)孵育,二抗以HRP-山羊抗小鼠IgG(1∶10 000)孵育后,化学发光进行显影.

1.10 免疫荧光实验分析Nek2亚细胞定位

用4%多聚甲醛固定7702,huh7和Hep3B细胞,经1% BSA封闭后,加入抗Nek2多克隆抗体(1∶500)孵育,二抗以荧光标记的山羊抗小鼠IgG(1∶1 000)孵育后,使用蔡司LSM 800激光共聚焦扫描显微镜观察Nek2亚细胞定位.

1.11 统计学方法

采用SPSS 17.0软件进行统计描述和推断,组间差异采用单因素方差分析,以P<0.05认为差异有统计学意义.

2 结 果

2.1 重组质粒pET30a(+)-Nek2的构建和鉴定

1.0%琼脂糖凝胶电泳结果显示,PCR扩增产物在约540bp处出现特异性条带,与目的基因Nek2片段长度相仿(图1,1泳道).将构建好的pET30a(+)-Nek2重组质粒转化大肠杆菌trans5ɑ感受态细胞中,菌液产物PCR验证阳性克隆与Nek2基因大小相符(图1,2泳道).将构建好的pET30a(+)-Nek2重组质粒进行Bam HⅠ和SalⅠ双酶切鉴定,可观察到约5 500bp的载体条带和540bp的目的基因条带,与预期基因片段大小一致(图1,3泳道).将阳性克隆菌液送测序,结果显示与目的基因片段序列一致,说明成功构建pET30a(+)-Nek2重组表达载体.
Fig.1 The construction of pET30a(+)-Nek2 vector

M:DNA marker; 1:PCR amplification product of Nek2 gene; 2:Colony PCR detection; 3:Bam HI and Sal I enzyme digestion of recombinant plasmid

图1 pET30a(+)-Nek2载体构建

Full size|PPT slide

2.2 重组人Nek2蛋白的表达及表达条件的优化

2.2.1 重组人Nek2蛋白表达形式分析 对IPTG诱导后重组菌株沉淀组分进行12% SDS-PAGE,结果显示,IPTG诱导后重组菌株沉淀组分在约29kDa处出现特异性的清晰条带(图2a),诱导后重组菌株上清组分,空载体对照菌株,未诱导的重组菌株上清和沉淀组分,空载体对照菌株均无条带出现,说明诱导的重组人Nek2蛋白主要以包涵体的形式存在.
2.2.2 重组人Nek2蛋白表达条件的优化 12% SDS-PAGE结果显示,随着温度升高,蛋白质表达量增加,28℃时蛋白质表达量最高(P<0.05),温度进一步上升,蛋白质表达量开始下降(图2b,图3a),说明重组人Nek2蛋白最适诱导温度为28℃.不同浓度的IPTG对蛋白质进行诱导,与0.4mmol/L和0.6mmol/L组相比,0.2mmol/L组蛋白质表达量相对较高(P<0.05),而与0.8mmol/L和1.0mmol/L组相比没有差异(P>0.05)(图2c,图3b),因此确定IPTG的最适诱导终浓度为0.2mmol/L.随着诱导时间的延长,重组人Nek2蛋白的表达量逐渐递增,32h时蛋白质表达量最高(P<0.05),超过32h蛋白质表达量开始下降(图2d,图3c),说明蛋白质最适诱导时间为32h.
Fig.2 Recombinant human Nek2 protein expression and optimization of induction conditions

(a)Expression of recombinant human Nek2 protein M:Maker; 1:Precipitation component of pET30a(+) induction;2:Precipitation component of pET30a(+) not induction;3:Precipitant component of pET30a(+)-Nek2 induction; 4:Precipitant component of pET30a (+)-Nek2 not induction;5:Supernatant component of pET30a(+) induction; 6:Supernatant component of pET30a(+) not induction; 7:Supernatant component of pET30a(+)-Nek2 induction;8:Supernatant component of pET30a(+)-Nek2 not induction (b) Expression of recombinant human Nek2 protein at different temperatures M:Marker; 1:After pET30a(+) induction; 2: pET30a(+) was not induced; 3:pET30a(+)-Nek2 was not induced; 4-7: pET30a(+) -Nek2 was induced at 18℃, 28℃, 37℃and 42℃ (c) Expression of recombinant human Nek2 protein at different IPTG concentrations M:Marker; 1:After pET30a(+) induction; 2:pET30a(+) was not induced ;3:pET30a(+) - Nek2 was not induced; 4-8: pET30a (+)-Nek2 was induced with 0.2mmol / L, 0.4mmol / L, 0.6mmol / L, 0.8mmol / L, 1.0mmol / L IPTG (d) Expression of recombinant human Nek2 protein at different times M:Marker; 1:After pET30a(+) induction; 2: pET30a(+) was not induced; 3: pET30a(+)-Nek2 was not induced; 4-12: pET30a(+) -Nek2 was induced at 4h, 8h, 12h, 16h, 20h, 24h, 28h, 32h, 36h

图2 重组人Nek2蛋白表达及条件优化

Full size|PPT slide

Fig.3 Gray value of the strip under different induction conditions

Different letters indicate P<0.05, the same letter indicates P>0.05 (a) Different temperature band gray value, F=1 339.962, P<0.05 (b) Different IPTG concentration band gray value, F=109.212, P<0.05 (c) Different induction time band gray value, F=138.483, P<0.05

图3 不同条件下电泳条带的灰度值

Full size|PPT slide

2.3 重组人Nek2蛋白的纯化和鉴定结果

12% SDS-PAGE结果显示,在约为29kDa处有一清晰条带且周围未见明显杂带(图4),与目的蛋白条带位置相符,凝胶成像系统分析蛋白质纯度大于95%;将重组人Nek2蛋白进行质谱分析,结果用Mascot 检索比对如图5所示,质谱鉴定5条多肽(划线部分)与数据库中Nek2蛋白氨基酸序列完全匹配.经BCA试剂盒定量,最终获得纯化后的Nek2蛋白浓度为1.35mg/ml.
Fig.4 Recombinant human Nek2 protein purification

M:Protein marker; 1:Recombinant human Nek2 protein after purification

图4 重组人Nek2蛋白纯化

Full size|PPT slide

Fig.5 Mass spectrometry identification of Mascot alignment

图5 Nek2质谱鉴定Mascot比对结果

Full size|PPT slide

2.4 抗Nek2多克隆抗体效价检测结果

图6可知,小鼠的抗Nek2多克隆抗体效价在1∶243 000以上,表明该抗体具有较高的效价.
Fig.6 Polyclonal antibody titer test results

图6 Nek2多克隆抗体效价检测结果

Full size|PPT slide

2.5 抗Nek2多克隆抗体特异性检测结果

图7可知,纯化的Nek2在29kDa处出现特异性条带,且根据Nek2含量的降低条带亮度也呈现递减的趋势,说明抗Nek2多克隆抗体具有良好的特异性.
Fig.7 Nek2 polyclonal antibody specific detection

图7 Nek2多克隆抗体特异性检测结果

Full size|PPT slide

2.6 Nek2亚细胞定位

检测了7702,huh7和Hep3B三种细胞的亚细胞定位,由图8可知,红色荧光主要分布于细胞质和细胞核,说明Nek2主要定位于细胞质和细胞核.
Fig.8 Nek2 subcellular localization

图8 Nek2亚细胞定位

Full size|PPT slide

3 讨 论

本研究运用原核表达系统对Nek2蛋白进行表达.由于大肠杆菌具有易于培养,繁殖迅速,产量高,易于纯化,遗传背景清楚,操作简便等优点,常作为原核表达系统中外源基因的受体菌[7].在原核表达系统中,影响重组蛋白表达的因素主要是诱导温度,IPTG终浓度和诱导时间[8].不同的蛋白质最适温度不同,本研究在28℃时蛋白质表达量高于18℃,37℃和42℃,说明该重组蛋白最适诱导温度为28℃.诱导温度过低,不利于大肠杆菌的生长,从而抑制蛋白质的表达;同时温度过高,大肠杆菌生长过快,不利于蛋白质的表达.IPTG对大肠杆菌的生长具有毒性作用,本研究IPTG在终浓度为0.2mmol/L 时蛋白质表达量大于0.4mmol/L和0.6mmol/L,而与0.8mmol/L和1.0mmol/L差别不大,所以最终选择浓度为0.2mmol/L IPTG对蛋白质进行诱导.在本研究中,随着诱导时间的延长,重组蛋白的表达量逐渐增加,到达32h时,蛋白质表达量最高,说明最适诱导时间为32h.诱导时间过长,一方面细菌会发生老化,不利于蛋白质的表达;另一方面会产生代谢产物,影响蛋白质质量.诱导时间过短,还没达到大肠杆菌的对数生长期,同样会影响蛋白质的表达.综上,通过对重组蛋白诱导表达条件进行优化,最终发现在28℃,180r/min条件下加入终浓度为0.2mmol/L 的IPTG诱导32h,Nek2蛋白产量最高.
本研究中Nek2重组蛋白在不同的温度下,都以包涵体的形式存在且该重组蛋白表达量高.有研究表明,高表达的蛋白质往往会聚集成不溶性,无活性的包涵体[9].本研究采用KCl染色切胶的方法纯化重组蛋白,因为该方法操作简便,省去了镍离子亲和层析方法纯化蛋白质的各种洗脱和透析工作,经济高效,降低了实验成本,节约了实验时间,而且用该方法纯化的目的蛋白还能保持原有的抗原性可以用于动物免疫[10].同时近期的研究表明,包涵体可作为口服疫苗传递载体且安全有效[11].
多克隆抗体生产过程简便,操作简单,产量大,成本低,且制备的多克隆抗体具有良好的抗体效价和特异性,因此研究者喜欢将其作为制备抗体的重要选择[12].本研究通过ELISA,Western blot和免疫荧光实验检测抗Nek2多克隆抗体效价和特异性,抗Nek2多克隆抗体效价达到1∶243 000以上,且具有良好的抗原特异性;免疫荧光实验结果显示Nek2主要定位于细胞质和细胞核,与文献报道[13]相一致,为后续研究Nek2在人类肿瘤中的表达情况奠定了基础.本课题组在前期研究中发现Nek2在肝癌中过量表达,且Nek2过表达与患者不良预后有关,提示Nek2是肝癌预后的生物标志物[14].有研究发现,Nek2 siRNA在胰腺癌皮下移植小鼠模型中能抑制肿瘤生长,在腹腔移植小鼠模型中能延长小鼠生存时间,并通过门静脉导管系统有效阻止肝脏转移的进展,提示Nek2是胰腺癌的有效治疗靶点[15].另一项研究发现了一种新的药物作用机制,INH (inhibitor for Nek2 and Hec1 binding)通过与Hec1的靶向结合形成了一个虚拟的死亡陷阱,从而触发Nek2降解并最终导致癌细胞死亡[16].目前Nek2检测方法主要有RT-PCR,Western blot和免疫组化[4],且进口的抗Nek2抗体价格昂贵,鉴于Nek2在肿瘤研究中具有重要作用,其相关检测试剂和药物的研发将具有非常广的应用价值.本研究结果为今后诊断试剂盒的研发以及相关抗体抑制剂的研究奠定了基础.

References

[1]
Fry A M, Meraldi P, Nigg E A . A centrosomal function for the human Nek2 protein kinase, a member of the NIMA family of cell cycle regulators. Embo Journal, 1998,17(2):470-481.
[2]
Federica B, Paronetto M P, Renato F , et al. Increased expression and nuclear localization of the centrosomal kinase Nek2 in human testicular seminomas. Journal of Pathology, 2010,217(3):431-441.
[3]
Tong H, Wang J, Chen H , et al. Transcriptomic analysis of gene expression profiles of stomach carcinoma reveal abnormal expression of mitotic components. Life Sciences, 2016,170:41-49.
[4]
Liu H, Liu B, Hou X , et al. Overexpression of NIMA-related kinase 2 is associated with poor prognoses in malignant glioma. Journal of Neuro-oncology, 2017,132(3):1-9.
[5]
Shi Y X, Yin J Y, Shen Y , et al. Genome-scale analysis identifies NEK2, DLGAP5 and ECT2 as promising diagnostic and prognostic biomarkers in human lung cancer. Scientific Reports, 2017,7(1):8072.
[6]
成金俊 . 淫羊藿苷单克隆抗体的制备及其ELISA法的建立和FLISA法的初探. 北京:北京中医药大学, 2015.
Cheng J J . Preparation of monoclonal antibody against icariin and establishment of ELISA method and preliminary study of FLISA method. Beijing:Beijing University of Chinese Medicine, 2015.
[7]
Long X, Gou Y, Luo M , et al. Soluble expression, purification, and characterization of active recombinant human tissue plasminogen activator by auto-induction in E. coli. Bmc Biotechnology, 2015,15(1):1-9.
[8]
杨隆兵, 国果, 马慧玲 , 等. 家蝇抗菌肽AMPs17蛋白原核表达条件的优化及其抗真菌活性检测. 中国生物工程杂志, 2019,39(4):24-31.
Yang L B, Guo G, Ma H L , et al. Optimization of prokaryotic expression conditions and antifungal activity detection of antibacterial peptide AMPs17 protein in Musca domestica. China Biotechnology, 2019,39(4):24-31.
[9]
张婷婷, 叶波平 . 包涵体蛋白质的复性研究进展. 药物生物技术, 2007,14(4):306-309.
Zhang T T, Ye B P . Advances in research on renaturation of inclusion body proteins. Pharmaceutical Biotechnology, 2007,14(4):306-309.
[10]
高慎阳, 查恩辉, 王珅 , 等. 一种"高性价比"切胶纯化原核表达蛋白的方法. 中国农学通报, 2010,26(22):24-26.
Gao S Y, Zha E H, Wang K , et al. A"cost-effective"method for purification of prokaryotic expression proteins in gel slices. Chinese Agricultural Science Bulletin, 2010,26(22):24-26.
[11]
Jiang X, Xia S, He X , et al. Targeting peptide-enhanced antibody and CD11c+ dendritic cells to inclusion bodies expressing protective antigen against ETEC in mice. The FASEB Journal, 2019,33(2):2836-2847.
[12]
陈云雨, 牛夏忆, 李淼 , 等. 大肠杆菌FtsZ蛋白原核表达及多克隆抗体的制备与鉴定. 生物工程学报, 2019,35(8):1-10.
Chen Y Y, Niu X Y, Li M , et al. Bacterial expression, preparation and identification of polyclonal antibody against Escherichia coli FtsZ. Chin J Biotech, 2019,35(8):1-10.
[13]
林双 . NEK2在原发性肝细胞肝癌中的表达及对其生物学特性的影响. 杭州:浙江大学, 2017.
Lin S . The expression of NEK2 in hepatocellular carcinoma and its effect on the biological characteristics. Hangzhou:Zhejiang University, 2017.
[14]
Li G, Zhong Y, Shen Q , et al. NEK2 serves as a prognostic biomarker for hepatocellular carcinoma. International Journal of Oncology, 2017,50(2):405-413.
[15]
Kokuryo T, Hibino S, Suzuki K , et al. Nek2 siRNA therapy using a portal venous port-catheter system for liver metastasis in pancreatic cancer. Cancer Science, 2016,107(9):1315-1320.
[16]
Hu C M, Zhu J, Guo X E , et al. Novel small molecules disrupting Hec1/Nek2 interaction ablate tumor progression by triggering Nek2 degradation through a death-trap mechanism. Oncogene, 2014,34(10):1220-1230.

RIGHTS & PERMISSIONS

Copyright reserved © 2020. Office of China Biotechnology.
PDF(877 KB)

1706

Accesses

0

Citation

Detail

Sections
Recommended

/